Patent details
301032 Product Name: Everolimus, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents
Basic Information
- Publication number:
- 301032
- Type:
- Certificate
- SPC Type:
- Medical
- Basic Patent Number:
- EP3342411
- Status:
- Withdrawn
- Application number:
- 301032
- Procedural language:
- Dutch
- First Applicant Residence Country:
- Switzerland (CH)
Marketing Authorization
- Marketing Authorization Number:
- EU/1/09/538/001-008 (C(2011)6162)
- Marketing Authorization Type:
- EEA
- Marketing Authorization Date:
- 30/08/2011
- Marketing Authorization Country:
- European Union (EU)
Dates
- Filing date:
- 20/02/2020
- First Marketing Authorization date:
- 30/08/2011
- Grant date:
- Activation date:
- Lapsed By Non Payment Annual Fee Date:
- Renunciation Date:
- NullificationDate:
- Registration date:
- 26/02/2020
- SPC/SPC Extension Expiration Date:
- 29/08/2026
- Lapsed By Expiration Date:
- Withdrawal date:
- 22/10/2020
- Revocation Date:
- Invalidity Date:
- Withdrawal Market Authorization Date:
- Refusal Date:
Applicant/holder
- From:
- 09/09/2020
- Name:
- Novartis Pharma AG
- Address:
- Lichtstrasse 35, 4056, Basel, Switzerland (CH)
Historical Applicant/holder
- From:
- 20/02/2020
- To:
- 09/09/2020
- Name:
- Novartis International Pharmaceutical AG
- Address:
- Lichtstrasse 35, 4056 Basel, Switzerland (CH)
- From:
- 20/02/2020
- To:
- 09/09/2020
- Name:
- Novartis Pharma AG
- Address:
- Lichtstrasse 35, 4056 BASEL, Switzerland (CH)
Agent
- Name:
- ir. M.F.J.M. Ketelaars c.s.
- From:
- 20/02/2020
- Address:
- NLO Postbus 29720, 2502 LS, Den Haag, Netherlands (NL)
- To:
Publication
Bulletin
1
- Bulletin Heading:
- VRV
- Journal edition number:
- 44/20
- Publication date:
- 28/10/2020
- Description:
- Lapse or annulment
2
- Bulletin Heading:
- CO
- Journal edition number:
- 39/20
- Publication date:
- 23/09/2020
- Description:
- Changes in the Netherlands Patent Register
3
- Bulletin Heading:
- SPC
- Journal edition number:
- 10/20
- Publication date:
- 08/05/2020
- Description:
- Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)
Deed
Change of owner(s)
- Change Kind/ Decision Type:
- Merge
- Deed Number:
- RC202001757A
- Date Registered:
- 09/09/2020
- License Effective Date:
- License Expiration Date:
- Scope of License:
- Deed Filer:
- ir. M.F.J.M. Ketelaars c.s.
- Journal Edition Number:
- Text:
- Deed Status:
- Country Code:
- Updated License Number:
- Terminated License Number:
Added Owner(s)
1
- Name:
- Novartis Pharma AG
- Address:
- Lichtstrasse 35, 4056, Basel, Switzerland (CH)
2
- Name:
- Novartis Pharma AG
- Address:
- Lichtstrasse 35, 4056 BASEL, Switzerland (CH)
Changed Pledgee
- Name:
- Address:
Removed Usufructuary
- Name:
- Address:
Added Usufructuary
- Name:
- Address:
Changed Usufructuary
- Name:
- Address:
| Filing date | Document type | Document Description | Number of pages | File Type | ||
|---|---|---|---|---|---|---|
| 26/10/2020 | Outgoing Correspondence | Letter confirmation withdrawal | 1 | /1/5/3/2/2/0800522351/docs/301032_1_374621l193.pdf | ||
| 22/10/2020 | SPC Documents | Accompanying letter SPC | 1 | /1/5/3/2/2/0800522351/docs/301032_2_supplprotectioncertificate20201023105346085.pdf | ||
| 23/07/2020 | Outgoing Correspondence | Letter to applicant | 3 | /1/5/3/2/2/0800522351/docs/301032_9_354350l173.pdf | ||
| 26/02/2020 | Outgoing Correspondence | Confirmation receipt request | 1 | /1/5/3/2/2/0800522351/docs/301032_16_328266l174.pdf | ||
| 20/02/2020 | SPC Documents | Annex SPC | 25 | /1/5/3/2/2/0800522351/docs/301032_0_supplprotectioncertificate20200226021633686.pdf | ||
| 20/02/2020 | SPC Documents | Annex SPC | 5 | /1/5/3/2/2/0800522351/docs/301032_3_supplprotectioncertificate20200226020002170.pdf | ||
| 20/02/2020 | SPC Documents | Annex SPC | 2 | /1/5/3/2/2/0800522351/docs/301032_4_supplprotectioncertificate20200226021633769.pdf | ||
| 20/02/2020 | SPC Documents | Summary of the characteristics of the product | 31 | /1/5/3/2/2/0800522351/docs/301032_5_supplprotectioncertificate20200226021633420.pdf | ||
| 20/02/2020 | SPC Documents | Annex SPC | 65 | /1/5/3/2/2/0800522351/docs/301032_6_supplprotectioncertificate20200226015020185.pdf | ||
| 20/02/2020 | SPC Documents | Annex SPC | 16 | /1/5/3/2/2/0800522351/docs/301032_7_supplprotectioncertificate20200226021633870.pdf | ||
| 20/02/2020 | Incoming Correspondence Paper | Accompanying letter incoming document | 5 | /1/5/3/2/2/0800522351/docs/301032_8_incomingcorrespondencepaper20200226015020085.pdf | ||
| 20/02/2020 | SPC Documents | Annex SPC | 17 | /1/5/3/2/2/0800522351/docs/301032_10_supplprotectioncertificate20200226020002010.pdf | ||
| 20/02/2020 | SPC Documents | Annex SPC | 2 | /1/5/3/2/2/0800522351/docs/301032_11_supplprotectioncertificate20200226020002090.pdf | ||
| 20/02/2020 | Application Form | First filed application form | 2 | /1/5/3/2/2/0800522351/docs/301032_12_applicationform20200226015019872.pdf | ||
| 20/02/2020 | SPC Documents | Marketing Authorization SPC | 4 | /1/5/3/2/2/0800522351/docs/301032_13_supplprotectioncertificate20200226020002261.pdf | ||
| 20/02/2020 | SPC Documents | Annex SPC | 2 | /1/5/3/2/2/0800522351/docs/301032_14_supplprotectioncertificate20200226021633510.pdf | ||
| 20/02/2020 | SPC Documents | Annex SPC | 16 | /1/5/3/2/2/0800522351/docs/301032_15_supplprotectioncertificate20200226021633605.pdf |